Skip to main content
. 2021 Oct 1;5(19):3748–3759. doi: 10.1182/bloodadvances.2020004146

Table 3.

Summary of TEAEs

TEAE by preferred term* All patients n (%) (N = 49)
Any grade Grade ≥3
Any TEAE 49 (100) 45 (92)
Nonhematologic TEAEs
 Diarrhea 32 (65) 5 (10)
 Fatigue 23 (47) 3 (6)
 Nausea 23 (47) 2 (4)
 Upper respiratory tract infection 19 (39) 0
 Dyspnea 17 (35) 3 (6)
 Insomnia 17 (35) 5 (10)
 Cough 16 (33) 0
 Vomiting 14 (29) 3 (6)
 Hypertension 13 (27) 8 (16)
 Dyspepsia 12 (24) 0
 Edema peripheral 12 (24) 0
 Headache 10 (20) 0
 Hypocalcemia 10 (20) 0
 Hypokalemia 10 (20) 1 (2)
 Sinusitis 10 (20) 0
 Abdominal pain 9 (18) 0
 Hypophosphatemia 9 (18) 5 (10)
 Pneumonia 9 (18) 6 (12)
 Hyperglycemia 8 (16) 3 (6)
 Hypomagnesemia 8 (16) 0
 Influenza 8 (16) 3 (6)
Hematologic TEAEs
 Lymphopenia 17 (35) 15 (31)
 Thrombocytopenia 15 (31) 4 (8)
 Neutropenia§ 11 (22) 6 (12)
 Leukopenia|| 11 (22) 6 (12)
 Anemia 9 (18) 4 (8)
*

TEAEs presented are those occurring in ≥15% of patients for any grade or in ≥10% of patients for grades 3 and 4.

Includes decreased lymphocyte count.

Includes decreased platelet count.

§

Includes decreased neutrophil count.

||Includes decreased white blood cell count.